RAPP
Rapport Therapeutics
$42.13
+$1.44 (+3.55%)Jul 27, 2026
Key metrics
The numbers that frame RAPP today
- Market cap
- $2.01B
- P/E (TTM)
- -18.8
- EV / FCF
- -24.1
- Gross margin
- 100%
- EV / Sales
- 97.4
- ROIC
- -31.2%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $13.64
- 52wk High
- $44.28
Growth
Revenue and earnings trend for RAPP
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RAPP
Is Rapport Therapeutics a good buy?
Hold. Rapport Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Rapport Therapeutics is selling at a high price.
What is the market capitalization of RAPP?
Rapport Therapeutics's market capitalization is $2.01B.
What is the P/E ratio for RAPP stock?
Rapport Therapeutics's current P/E ratio is -18.8.
What is the 52-week high for RAPP stock?
The 52-week high for Rapport Therapeutics is $44.28. The current close of $42.13 is 4.9% below that high.
What is the 52-week low for RAPP stock?
The 52-week low for Rapport Therapeutics is $13.64. The current close of $42.13 is 208.8% above that low.
Does RAPP stock pay dividends?
Rapport Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RAPP?
Rapport Therapeutics's Debt / Equity ratio is 0.02.